A simple breath test could prove groundbreaking in the diagnosis of mesothelioma and make the aggressive cancer much easier to treat at an earlier stage.
NEW YORK – UK-based startup Oxford Cancer Analytics is using the $11 million it has raised in a Series A financing to further develop and commercialize its protein-based lung cancer screening assay.